Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Methods and agents are disclosed for modulating the interaction of ?-catenin or ?-catenin with CBP or p300. Agents that increase the binding of CBP to ?-catenin are associated with enhancing the ?-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells.

Abstract: The invention provides ?-mimetic structure of formula (I), wherein A is —(C?O)—(CHR3)— or —(C?O)—; B is —(NR5)— or —(CHR6)—; D is —(C?O)—(CHR7)— or —(C?O)—; E is -(ZR8)— or —(C?O)—, where Z is nitrogen or CH; —(XR9)n—, —(CHR10)—(NR6)—, —(C?O)—(XR12)—, —(C?N—W—R1)—, —(C?O)—, —(X—(C?O)—R13)—, —(X—(C?O)—NR13R14)—, —(X—(SO2)—R13)—, or —(X—(C?O)—OR13)—, where X is nitrogen or CH, and n=0 or 1; W is —Y(C?O)—, —(C?O)—(NH)—, —(SO2)—, —(CHR14)—, —(C?O)—(NR15)—, substituted or unsubstituted oxadiazole, substituted or unsubstituted triazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted 4,5-dihydrooxazole, substituted or unsubstituted 4,5-dihydrothiazole, substituted or unsubstituted 4,5-dihydroimidizole, or nothing, where Y is oxygen or sulfur; and R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, R11, R12, R13, R14, and R15 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, the remainder of the molecule, a linker and a solid support, and ster

Abstract: The present invention provides compounds and methods for modulating transcription activated by ?-catenin/TCF, such as the selective inhibition of genes targeted by the Wnt/?-catenin pathway.

Abstract: There are disclosed ?-sheet mimetics and methods relating to the same for imparting or stabilizing the ?-sheet structure of a peptide, protein or molecule. In one aspect, ?-sheet mimetics are disclosed having utility as protease inhibitors in general and, more specifically, as serine protease inhibitors such as thrombin, elastase and Factor X inhibitors. In one embodiment, the ?-sheet mimetic is a thrombin inhibitor.

Abstract: A product, method and kit for making ice cream treats which allows a user to pick their own flavor(s) of ice cream, add toppings to the inside or outside of the ice cream treat and choose different covers for the ice cream.

Abstract: A holder for holding an object which melts or drips or leaves imprints on one's fingers comprising a handle and a protrusion section. The device can further comprise a slip prevention disk with is located between said handle and said protrusion section.

Abstract: The invention provides ?-mimetic structure of formula (I), wherein A is —(C?O)—(CHR3)— or —(C?O)—; B is —(NR5)— or —(CHR6)—; D is —(C?O)—(CHR7)— or —(C?O)—; E is -(ZR8)— or —(C?O)—, where Z is nitrogen or CH; —(XR9)n—, —(CHR10)—(NR6)—, —(C?O)—(XR12)—, —(C?N—W—R1)—, —(C?O)—, —(X—(C?O)—R13)—, —(X—(C?O)—NR13R14)—, —(X—(SO2)—R13)—, or —(X—(C?O)—OR13)—, where X is nitrogen or CH, and n=0 or 1; W is —Y(C?O)—, —(C?O)—(NH)—, —(SO2)—, —(CHR14)—, —(C?O)—(NR15)—, substituted or unsubstituted oxadiazole, substituted or unsubstituted triazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted 4,5-dihydrooxazole, substituted or unsubstituted 4,5-dihydrothiazole, substituted or unsubstituted 4,5-dihydroimidazole, or nothing, where Y is oxygen or sulfur; and R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, R11, R12, R13, R14, and R15 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, the remainder of the molecule, a linker and a solid support, and ster

Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of fibrotic diseases, such as pulmonary fibrosis.

Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the reversal of fibrotic conditions, such as pulmonary fibrosis.

Abstract: The invention provides ?-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein ?-mimetic compounds are used to treat fibrotic disorders.

Abstract: The present invention comprises an infant carrier and a mating base which combine to form an infant carrier/car seat combination. The infant carrier has a seat belt system within it to properly secure the infant. When the infant carrier is attached to the base, and the infant carrier seat belt system is not fastened, a notification is generated. When the infant carrier is not properly fastened to the base, a notification may also be generated. Additionally, a confirmation notification may be generated when the seat belt is fastened and the infant carrier is properly fastened to the base. This notification may comprise audible, visual, or tactile indications, or a combination of the aforementioned indications. The indications may include, but are not limited to, a buzzer, a flashing light, or a vibrator in the handle of the infant carrier.

Abstract: A low-latency storage memory system is built from multiple memory units such as high-density random access memory. Multiple access ports provide access to memory units and send the resultant data out interface ports. The memory units communicate with the access ports through an interconnected mesh to allow any access port to access any memory unit. An address virtualization mechanism using address translators allows any access port of the memory storage system to access requested data as abstract objects without regard for the physical memory unit that the data is located in, or the absolute memory addresses within that memory unit.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Methods and agents are disclosed for modulating the interaction of ?-catenin or ?-catenin with CBP or p300. Agents that increase the binding of CBP to ?-catenin are associated with enhancing the ?-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells, as well as embryonic stem cells.

Abstract: The invention provides ?-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein a-mimetic compounds are used to treat cancer stem cells.

Abstract: A system includes multiple input ports that forward received data (e.g., data packets) to each of multiple queues. Data received at the input ports of the system can be somewhat random or “bursty” at times. That is, the input ports can receive data at a variable bit rate or unspecified bit rate from an internal system source or an external source such as an FTP (File Transfer Protocol) server or SCSI disk array. The queues output data at a constant bit rate. A two-dimensional scheduler associated with the system forces random inbound server traffic from the input ports to adhere to a QoS (Quality of Service) agreement such that the random nature of the inbound traffic does not negatively affect the deterministic guarantees of existing server traffic output from the queues. In other words, techniques herein ensure adherence to QoS requirements among the data flows, without overflowing the queues.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.